Popular on Amzeal
- K4Connect Joins AgeTech Collaborative™ From AARP - 121
- IOTA Unveils New Features to Revolutionize IoT and DeFi - 113
- Attorney Lindsay Graves Joins Bisnar Chase's Personal Injury Litigation Team - 111
- New Case Study: 37 Years of Improving Emergency Communications at Rush Copley Medical Center - 109
- AltShift WP Thrilled to Welcome Two New Clients: Arista Health Care and Ryan's Roofing & Repair - 105
- New Integrated Solution Simplifies AI Factory Buildout - 104
- Kemeny, Ramp & Renaud, LLC Recognized as A Top New Jersey Personal Injury Law Firms in NJBIZ's 2024 Reader's Rankings Awards - 103
- 10 Key Points to learn about local Custom Home Builders Before Considering Houses in Huntsville, AL
- The Common Thread That Unites Us All
- Sparkling Logic Seamlessly Integrates Machine Learning and AI into Automated Decision Making in Latest Washington Release
Similar on Amzeal
- 418,000 Kids Aged 0-5 on Psych Drugs: Campaign for "De-Prescribing"
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
- Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
- Dr. Barrie Matthews of Big Sky Smile Center Speaks at the Full Arch Growth Conference, Inspiring Dentists Nationwide
- Dr. Sathish Palayam Speaks at the Full Arch Growth Conference, Sharing Insights to Revolutionize Patient Care!
- OneSolution® Dental Implant Centers Offers Advanced Zygomatic Dental Implant Solutions
- Speranza Dental Implant Center's New Website Launch!
- "Federal Complaint Filed: David Medeiros Uncovers Medicaid Mismanagement, ADA Violations, and Systemic Failures in Connecticut"
- Introducing Feelness: A Revolutionary Solution for Physical Self-Care Without the Fitness Lifestyle
- Time to Investigate Mental Health Research Waste on Bizarre Animal Studies
Empowering Asthma Care: Bedfont® Scientific Limited Provides Vital Support for FeNO Testing
Amzeal News/10582986
Bedfont® outlines key NICE Guideline updates and offers support for healthcare professionals navigating the changes.
MAIDSTONE, U.K. - Amzeal -- Bedfont® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in designing and manufacturing medical breath analysis devices, welcomes the recent update to the National Institute for Health and Care Excellence (NICE) guidelines on asthma management.
Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing and managing asthma. Nitric oxide is a gas found in exhaled breath that indicates airway inflammation commonly found in eosinophilic asthma.
The previous guidelines for asthma management from NICE recommended FeNO testing alongside other objective tests, such as spirometry and peak flow. A FeNO reading of over 40 parts per billion (ppb) in adults and 35 ppb in children suggested a diagnosis of asthma if carried out with a positive spirometry or peak flow result.
More on Amzeal News
So, what's new? NICE released the most recent asthma guidelines on Wednesday 27th of November, which recommends a blood test to measure eosinophil levels, or a FeNO test to diagnose asthma in adults. A FeNO test is recommended as the first-line test for an asthma diagnosis in children. Confirmation of a positive asthma diagnosis is a FeNO level exceeding 50 ppb in adults and 35 ppb in children.
It is also proposed that FeNO tests should be offered at regular adult asthma reviews for monitoring, including before and after changing asthma medication. A FeNO test should also be undertaken if a patient presents with poorly controlled asthma.
Jason Smith, CEO at Bedfont® comments "We welcome the updated NICE guidelines, which provide even greater clarity and emphasis on the role of FeNO testing in asthma care. These updates underscore the importance of FeNO testing as an essential tool in improving diagnostic accuracy and tailoring treatment plans to individual patient needs. At Bedfont® we are proud to support healthcare professionals with our innovative NObreath® (https://www.nobreathfeno.com/) FeNO testing device that aligns with the latest clinical guidance, ultimately helping to deliver better outcomes for people with asthma."
More on Amzeal News
In light of the changes to asthma care and management recommendations, Bedfont® will host various educational resources, such as webinars and articles, to discuss these changes and what they mean for healthcare professionals carrying out FeNO tests.
For a more in-depth look at the guideline updates, read our latest article here (https://www.bedfont.com/new-nice-guidelines-for-asthma-feno-testing-and-the-nobreath-device-in-adult-and-paediatric-care/).
References
Asthma pathway (BTS, NICE, SIGN) [Internet]. National Institute for Health and Care Excellence. 2024. [Cited Wednesday 27th November 2024]. Available from: https://www.nice.org.uk/guidance/ng244
Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing and managing asthma. Nitric oxide is a gas found in exhaled breath that indicates airway inflammation commonly found in eosinophilic asthma.
The previous guidelines for asthma management from NICE recommended FeNO testing alongside other objective tests, such as spirometry and peak flow. A FeNO reading of over 40 parts per billion (ppb) in adults and 35 ppb in children suggested a diagnosis of asthma if carried out with a positive spirometry or peak flow result.
More on Amzeal News
- OpenID Foundation returns to Gartner IAM Summit to showcase interoperability in action
- New Book Features Jose Silva's Ultimate Consciousness Expansion Technique
- Solana vs Ethereum: The Blockchain Showdown
- Rising Stars Romulus First Debuts Genre-Bending Album "Reality"
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
So, what's new? NICE released the most recent asthma guidelines on Wednesday 27th of November, which recommends a blood test to measure eosinophil levels, or a FeNO test to diagnose asthma in adults. A FeNO test is recommended as the first-line test for an asthma diagnosis in children. Confirmation of a positive asthma diagnosis is a FeNO level exceeding 50 ppb in adults and 35 ppb in children.
It is also proposed that FeNO tests should be offered at regular adult asthma reviews for monitoring, including before and after changing asthma medication. A FeNO test should also be undertaken if a patient presents with poorly controlled asthma.
Jason Smith, CEO at Bedfont® comments "We welcome the updated NICE guidelines, which provide even greater clarity and emphasis on the role of FeNO testing in asthma care. These updates underscore the importance of FeNO testing as an essential tool in improving diagnostic accuracy and tailoring treatment plans to individual patient needs. At Bedfont® we are proud to support healthcare professionals with our innovative NObreath® (https://www.nobreathfeno.com/) FeNO testing device that aligns with the latest clinical guidance, ultimately helping to deliver better outcomes for people with asthma."
More on Amzeal News
- The Score Album for "The Lost Weekend: A Love Story" Released Today
- Youth Group Makes History as First Visitors to National Electronics Museum
- Lucid Data Hub Now Available in the Microsoft Azure Marketplace!
- Pololikashvili runs for re-election as UN Tourism Secretary General for 2026-2029 term
- Sequentex Achieves Prestigious Women-Owned Small Business (WOSB) Certification
In light of the changes to asthma care and management recommendations, Bedfont® will host various educational resources, such as webinars and articles, to discuss these changes and what they mean for healthcare professionals carrying out FeNO tests.
For a more in-depth look at the guideline updates, read our latest article here (https://www.bedfont.com/new-nice-guidelines-for-asthma-feno-testing-and-the-nobreath-device-in-adult-and-paediatric-care/).
References
Asthma pathway (BTS, NICE, SIGN) [Internet]. National Institute for Health and Care Excellence. 2024. [Cited Wednesday 27th November 2024]. Available from: https://www.nice.org.uk/guidance/ng244
Source: Bedfont Scientific Ltd.
Filed Under: Health
0 Comments
Latest on Amzeal News
- Network Services Group Partners with Huntress for Cybersecurity
- OneSolution® Dental Implant Centers Offers Advanced Zygomatic Dental Implant Solutions
- Security Experts to Host Conference on Deepfakes and Cybersecurity in 2025
- Alice In Farmland Launches New Crypto Price Prediction Service for MANA, Sandbox, and AVAX Investors
- Pittsburgh Professional Women invites all Women and Allies to MONEY CLUB
- Speranza Dental Implant Center's New Website Launch!
- Education Through Music-Los Angeles to Host 19th Year Benefit Gala on Friday December 6th at Skirball Cultural Center
- Celebrating A Decade Of Young Storytellers: The 10th Annual Flint Youth Film Festival Opens For Entries
- Mobility Infotech: A Leader in Custom Software Development Services in 2024
- Clowder to Host Client Showcase Featuring Tips from Award-Winning Mobile App Launch
- Tween Magazine Launches to Empower and Inspire Preteen Girls
- IOTAP (Work 365) Earns SOC 2 Type II Compliance, Reinforcing Data Security Leadership
- Artisan Teck Excellence in Software Development
- ResmarkWeb Unveils Nine AI-Driven Strategies to Skyrocket Direct Travel Bookings
- Lake Norman Philharmonic - Annual Holiday Concert
- What Insights From 7,500 UK Workers Reveal About The Digital Skills Gap
- ThoroughCare Integrates with PointClickCare to Enhance Coordinated Care
- Invenio IT Expands Cybersecurity Offerings with Datto Antivirus (AV)
- "Federal Complaint Filed: David Medeiros Uncovers Medicaid Mismanagement, ADA Violations, and Systemic Failures in Connecticut"
- Intersys Expands 24/7 Cyber Security Services to Australian Businesses Amid Landmark Cyber Security Act